Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming and the maintenance of cell identity. Here are details of Mogrify‘s latest funding round :
🚀 Launch
2019
🏭 Industry
Biotechnology
🧠Management
DR. DARRIN M. DISLEY OBE (CEO), JOE FOSTER (COO), DR. DAVID MATHEWS (SENIOR SCIENTIFIC DIRECTOR), DR. AIDA MORENO-MORAL (DIRECTOR, CELL INFORMATICS), DR. ALUN BARNARD (DIRECTOR, OPHTHALMOLOGY), DR. DAVID ANDERSON (DIRECTOR, TECHNOLOGY)
💸 Funding & Investors
| INVESTMENT (October 2023) | $10 million (Series A) |
| INVESTORS (October 2023) | The round, which brought total amount to $46M in the round, was led by Astellas Venture Management and Parkwalk Advisors with participation from Ahren Innovation Capital, Trend Investment Group, and Dr Jonathan Milner, co-founder of Abcam Plc. |
🎯 Funding purpose
Further advancement of its pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.
🌐 Country HQ
UK (London)